ReviewNature reviews. Clinical oncology2014
Future directions in the prevention of prostate cancer.
Review in Nature reviews. Clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Identification of the mitochondrial protein POLRMT as a potential therapeutic target of prostate cancer.Cell death & disease · 2023Article
- GNE-493 inhibits prostate cancer cell growth via Akt-mTOR-dependent and -independent mechanisms.Cell death discovery · 2022Article
- Exploration of Long-Chain Vitamin E Metabolites for the Discovery of a Highly Potent, Orally Effective, and Metabolically Stable 5-LOX Inhibitor that Limits Inflammation.Journal of medicinal chemistry · 2021Article
- Cross-Talk between Oxidative Stress and mOxidative medicine and cellular longevity · 2021Review
- Application of Anti-Inflammatory Agents in Prostate Cancer.Journal of clinical medicine · 2020Review
- Endogenous metabolites of vitamin E limit inflammation by targeting 5-lipoxygenase.Nature communications · 2018Article
- Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications.Cancer letters · 2018Review
- A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer.Scientific reports · 2017Article
- Hollow boron nitride nanospheres as boron reservoir for prostate cancer treatment.Nature communications · 2017Article
- Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism.NPJ precision oncology · 2017Article
- Prostate Cancer Xenograft Inhibitory Activity and Pharmacokinetics of Decursinol, a Metabolite of Angelica gigas Pyranocoumarins, in Mouse Models.The American journal of Chinese medicine · 2017Article
- Is There a Future for Chemoprevention of Prostate Cancer?Cancer prevention research (Philadelphia, Pa.) · 2016Article
- PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.Biomaterials · 2016Article
- Broccoli-Derived Sulforaphane and Chemoprevention of Prostate Cancer: From Bench to Bedside.Current pharmacology reports · 2015Article
- Glycogen synthase kinase-3: a potential preventive target for prostate cancer management.Urologic oncology · 2015Review
- A Perspective on Prostate Carcinogenesis and Chemoprevention.Current pharmacology reports · 2015Article
- Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice.Cancer prevention research (Philadelphia, Pa.) · 2015Article
- Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene.The American journal of pathology · 2015Article
- MicroRNA-143 acts as a tumor suppressor by targeting hexokinase 2 in human prostate cancer.American journal of cancer research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The high global incidence of prostate cancer has led to a focus on chemoprevention strategies to reduce the public health impact of the disease. Early studies indicating that selenium and vitamin E might protect against prostate cancer encouraged large-scale studies that produced mixed clinical results. Next-generation prostate cancer prevention trials validated the impact of 5α-reductase inhibitors in hormone-responsive prostate cancer, and these results were confirmed in follow-up studies. Other interventions on the horizon, involving both dietary and pharmacological agents, hold some promise but require further investigation to validate their efficacy. In this Review, we discuss the clinical and preclinical evidence for dietary and pharmacological prevention of prostate cancer and give an overview of future opportunities for chemoprevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.